TaiRx, Inc.
TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various … Read more
TaiRx, Inc. (6580) - Net Assets
Latest net assets as of June 2025: NT$577.11 Million TWD
Based on the latest financial reports, TaiRx, Inc. (6580) has net assets worth NT$577.11 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$609.18 Million) and total liabilities (NT$32.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$577.11 Million |
| % of Total Assets | 94.74% |
| Annual Growth Rate | 7.22% |
| 5-Year Change | -18.73% |
| 10-Year Change | N/A |
| Growth Volatility | 43.61 |
TaiRx, Inc. - Net Assets Trend (2019–2024)
This chart illustrates how TaiRx, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for TaiRx, Inc. (2019–2024)
The table below shows the annual net assets of TaiRx, Inc. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$648.51 Million | -16.12% |
| 2023-12-31 | NT$773.12 Million | +61.36% |
| 2022-12-31 | NT$479.12 Million | -29.11% |
| 2021-12-31 | NT$675.86 Million | -15.30% |
| 2020-12-31 | NT$797.95 Million | +74.39% |
| 2019-12-31 | NT$457.57 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to TaiRx, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 83885900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$1.11 Billion | 170.88% |
| Other Comprehensive Income | NT$14.38 Million | 2.22% |
| Other Components | NT$1.16 Billion | 178.95% |
| Total Equity | NT$647.17 Million | 100.00% |
TaiRx, Inc. Competitors by Market Cap
The table below lists competitors of TaiRx, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mostostal Zabrze - Holding SA
WAR:MSZ
|
$49.40 Million |
|
Data Image Corporation
TW:3168
|
$49.41 Million |
|
ITM Semiconductor Co. Ltd
KQ:084850
|
$49.42 Million |
|
Eimco Elecon (India) Limited
NSE:EIMCOELECO
|
$49.44 Million |
|
Tze Shin International Co Ltd
TW:2611
|
$49.39 Million |
|
209640
KQ:209640
|
$49.39 Million |
|
Nanoform Finland Plc
HE:NANOFH
|
$49.39 Million |
|
ONEJOON Co. Ltd.
KQ:382840
|
$49.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TaiRx, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 771,796,000 to 647,174,000, a change of -124,622,000 (-16.1%).
- Net loss of 138,835,000 reduced equity.
- New share issuances of 7,032,000 increased equity.
- Other comprehensive income increased equity by 16,226,000.
- Other factors decreased equity by 9,045,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-138.84 Million | -21.45% |
| Share Issuances | NT$7.03 Million | +1.09% |
| Other Comprehensive Income | NT$16.23 Million | +2.51% |
| Other Changes | NT$-9.04 Million | -1.4% |
| Total Change | NT$- | -16.15% |
Book Value vs Market Value Analysis
This analysis compares TaiRx, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.84x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 2.24x to 2.84x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$7.46 | NT$16.70 | x |
| 2020-12-31 | NT$11.72 | NT$16.70 | x |
| 2021-12-31 | NT$7.42 | NT$16.70 | x |
| 2022-12-31 | NT$5.35 | NT$16.70 | x |
| 2023-12-31 | NT$8.40 | NT$16.70 | x |
| 2024-12-31 | NT$5.88 | NT$16.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TaiRx, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1688.58%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.06x
- Recent ROE (-21.45%) is above the historical average (-30.05%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -48.26% | -6900.03% | 0.01x | 1.08x | NT$-262.89 Million |
| 2020 | -20.21% | -4745.04% | 0.00x | 1.06x | NT$-238.26 Million |
| 2021 | -18.62% | -2443.36% | 0.01x | 1.05x | NT$-193.07 Million |
| 2022 | -44.28% | -3056.15% | 0.01x | 1.12x | NT$-259.36 Million |
| 2023 | -27.51% | -4177.33% | 0.01x | 1.08x | NT$-289.47 Million |
| 2024 | -21.45% | -1688.58% | 0.01x | 1.06x | NT$-203.55 Million |
Industry Comparison
This section compares TaiRx, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TaiRx, Inc. (6580) | NT$577.11 Million | -48.26% | 0.06x | $49.39 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |